ResearcherUniversity Hospitals of ClevelandActive in the last 2 years

Hanna H. Kakish

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1282-5443; OpenAlex author ID A5064989906. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Understanding surgical attrition for "resectable" pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.11.008 ↗
Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mohamedraed Elshami · 2 shared papers, 2022–2024 · strength 0.35
- Paper Understanding surgical attrition for "resectable" pancreatic cancer. DOI 10.1016/j.hpb.2023.11.008 ↗
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
Richard S. Hoehn · 2 shared papers, 2022–2024 · strength 0.35
- Paper Understanding surgical attrition for "resectable" pancreatic cancer. DOI 10.1016/j.hpb.2023.11.008 ↗
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
John Brian Ammori · 2 shared papers, 2022–2024 · strength 0.35
- Paper Understanding surgical attrition for "resectable" pancreatic cancer. DOI 10.1016/j.hpb.2023.11.008 ↗
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
Lee Mayer Ocuin · 2 shared papers, 2022–2024 · strength 0.35
- Paper Understanding surgical attrition for "resectable" pancreatic cancer. DOI 10.1016/j.hpb.2023.11.008 ↗
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
Jeffrey M. Hardacre · 2 shared papers, 2022–2024 · strength 0.35
- Paper Understanding surgical attrition for "resectable" pancreatic cancer. DOI 10.1016/j.hpb.2023.11.008 ↗
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
Jordan Michael Winter · 2 shared papers, 2022–2024 · strength 0.35
- Paper Understanding surgical attrition for "resectable" pancreatic cancer. DOI 10.1016/j.hpb.2023.11.008 ↗
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
Luke Daniel Rothermel · 1 shared paper, 2022 · strength 0.14
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
Jonathan J. Hue · 1 shared paper, 2022 · strength 0.14
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗
David Lawrence Bajor · 1 shared paper, 2022 · strength 0.14
- Paper Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenoc… DOI 10.1016/j.hpb.2022.07.007 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.